Pathophysiology of Lung Disease and Wound Repair in Cystic Fibrosis

被引:15
|
作者
Conese, Massimo [1 ]
Di Gioia, Sante [1 ]
机构
[1] Univ Foggia, Dept Med & Surg Sci, Lab Expt & Regenerat Med, I-71122 Foggia, Italy
关键词
cystic fibrosis; CFTR; airway epithelium; wound healing; EGF/EGFR; epithelial-mesenchymal transition; curcumin; CFTR modulators; mesenchymal stem cells; AIRWAY EPITHELIAL-CELLS; TRANSMEMBRANE-CONDUCTANCE-REGULATOR; GROWTH-FACTOR-BETA; TIGHT JUNCTION ORGANIZATION; GENE-EXPRESSION PROFILES; VITAMIN-A-DEFICIENCY; PSEUDOMONAS-AERUGINOSA; IN-VITRO; MESENCHYMAL TRANSITION; TGF-BETA;
D O I
10.3390/pathophysiology28010011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cystic fibrosis (CF) is an autosomal recessive, life-threatening condition affecting many organs and tissues, the lung disease being the chief cause of morbidity and mortality. Mutations affecting the CF Transmembrane Conductance Regulator (CFTR) gene determine the expression of a dysfunctional protein that, in turn, triggers a pathophysiological cascade, leading to airway epithelium injury and remodeling. In vitro and in vivo studies point to a dysregulated regeneration and wound repair in CF airways, to be traced back to epithelial CFTR lack/dysfunction. Subsequent altered ion/fluid fluxes and/or signaling result in reduced cell migration and proliferation. Furthermore, the epithelial-mesenchymal transition appears to be partially triggered in CF, contributing to wound closure alteration. Finally, we pose our attention to diverse approaches to tackle this defect, discussing the therapeutic role of protease inhibitors, CFTR modulators and mesenchymal stem cells. Although the pathophysiology of wound repair in CF has been disclosed in some mechanisms, further studies are warranted to understand the cellular and molecular events in more details and to better address therapeutic interventions.
引用
收藏
页码:155 / 188
页数:34
相关论文
共 50 条
  • [21] Origins of Cystic Fibrosis Lung Disease
    Munder, Antje
    Tuemmler, Burkhard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (16): : 1574 - 1574
  • [22] Pathophysiology and therapy of cystic fibrosis
    Bachert, C
    [J]. HNO, 1996, 44 (04) : 167 - 168
  • [23] Pancreatic pathophysiology in cystic fibrosis
    Gibson-Corley, Katherine N.
    Meyerholz, David K.
    Engelhardt, John F.
    [J]. JOURNAL OF PATHOLOGY, 2016, 238 (02): : 311 - 320
  • [24] PULMONARY PATHOPHYSIOLOGY IN CYSTIC FIBROSIS
    BEIER, FR
    RENZETTI, AD
    MITCHELL, M
    WATANABE, S
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1966, 94 (03): : 430 - &
  • [25] PATHOPHYSIOLOGY OF CYSTIC-FIBROSIS
    WOLFF, D
    STUTZIN, A
    [J]. ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES, 1990, 23 (04): : 277 - 284
  • [26] Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications
    Anabtawi, Abeer
    Trang Le
    Putman, Melissa
    Tangpricha, Vin
    Bianchi, Maria Luisa
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2019, 18 : S48 - S55
  • [27] Cystic fibrosis lung disease: Current perspectives
    Jung, Jin-A
    [J]. ALLERGY ASTHMA & RESPIRATORY DISEASE, 2020, 8 (01): : 3 - 8
  • [28] Clinical presentation of lung disease in cystic fibrosis
    Stahl, Mirjam
    [J]. RADIOLOGE, 2020, 60 (09): : 774 - 780
  • [29] Antioxidant supplementation for lung disease in cystic fibrosis
    Ciofu, Oana
    Smith, Sherie
    Lykkesfeldt, Jens
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10):
  • [30] Inflammatory mediators in cystic fibrosis lung disease
    Berger, M
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2002, 23 (01) : 19 - 25